PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

550 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 38 from 1 topic.Sort: Newest | Oldest
Mirikizumab sustains multidomain UC remission through four years
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Sands BE, Clemow DB, D'Haens G, et al.
Jun 1, 2026 · Published in: Inflammatory Bowel Diseases

Four-year study shows lasting ulcerative colitis remission with mirikizumab.

AASLD Adds Semaglutide to MASH Practice Guidance With NIT-Based Selection
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
Bansal MB, Patton H, Morgan TR, et al.
May 1, 2026 · Published in: Hepatology (Baltimore, Md.)

Semaglutide offers new hope for MASH management with significant fibrosis improvement.

Resmetirom Update: Positioning the First Approved MASH Therapy
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Van Kleef LA, Michel M, Alkhouri N, et al.
Jan 1, 2026 · Published in: Drug Design, Development and Therapy

Resmetirom is the first drug to reverse MASH and fibrosis.

Resmetirom Efficacy Holds With GLP-1 or SGLT2 Background; Weight Loss Amplifies It
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Noureddin M, Rinella M, Taub R, et al.
Dec 1, 2025 · Published in: Alimentary Pharmacology & Therapeutics

Resmetirom shows promise in MASH, especially with weight loss.

EASL-EASD-EASO Guidelines Redefine MASLD Care With Resmetirom Entry
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)
Sep 1, 2024 · Published in: Journal of Hepatology

New guidelines transform MASLD management with non-invasive testing and targeted therapies.

Survodutide Improves MASH Histology Across Doses in Phase 2
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Sanyal AJ, Bedossa P, Fraessdorf M, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine

Survodutide shows promise in treating MASH without worsening fibrosis.

Tirzepatide Resolves MASH but Fibrosis Benefit Remains Unproven
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Loomba R, Hartman ML, Lawitz EJ, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine

Tirzepatide offers potential new hope for MASH management.

Resmetirom Achieves Dual Histologic Endpoints in NASH Fibrosis
Analysis Gastroenterology / Hepatology Practice-changing Grade: High
Harrison SA, Bedossa P, Guy CD, et al.
Feb 8, 2024 · Published in: The New England Journal of Medicine

Resmetirom could be a breakthrough treatment for NASH with liver fibrosis.